Bristol-Myers Says Celgene Deal On Track For Q3 Close After Shareholder Approval

Bristol-Myers Squibb (BMY) announced that its shareholders voted to approve the issuance of shares of Bristol-Myers common stock in connection with the company's pending merger with Celgene (CELG). More than 75% of the shares voted at the special meeting were voted in favor of the Celgene merger agreement.

Image result for Bristol-Myers Squibb

The transaction remains on track to close in Q3 of 2019, subject to regulatory approvals, Bristol-Myers said. "We are pleased with the outcome of today's Special Meeting and thank our shareholders for their support for this combination," said Giovanni Caforio, CEO of Bristol-Myers Squibb. "Together with Celgene, we will create a premier innovative biopharma company with leading scientific capabilities that is well positioned to address the needs of patients through high-value innovative medicines. We look forward to bringing the companies together, which we believe will deliver significant shareholder value".

Disclaimer: TheFly's news is intended for informational purposes only and does not claim to be actionable for investment decisions. Read more at  more

How did you like this article? Let us know so we can better customize your reading experience. Users' ratings are only visible to themselves.


Leave a comment to automatically be entered into our contest to win a free Echo Show.